Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4726170 | 0.86 | CFTR (0.61) | CFTRGOPCGAAPKMLMNA | |
| SCHEMBL1820782 | 0.85 | CYP2D6 (0.48) | CFTRGOPCGAAPKMLMNA | |
| SCHEMBL4726524 | 0.83 | CFTR (0.46) | CFTRGOPCGAAPKMLMNA | |
| SCHEMBL4727744 | 0.79 | CFTR (0.44) | CFTRGOPCGAAPKMLMNA | |
| SCHEMBL19021292 | 0.79 | CFTR (0.73) | CFTRGOPCGAAPKMLMNA | |
| SCHEMBL7843306 | 0.77 | CFTR (0.46) | CFTRGOPCGAAPKMLMNA | |
| SCHEMBL7573541 | 0.75 | GAA (0.44) | CFTRGOPCGAAPKMLMNA | |
| SCHEMBL19010401 | 0.73 | CFTR (0.63) | CFTRGOPCGAAPKMLMNA | |
| SCHEMBL4728501 | 0.73 | HCAR3 (0.44) | CFTRGOPCLMNACYP3A4MAPT | |
| SCHEMBL11452421 | 0.72 | KCNQ2 (0.40) | SMN1; SMN2CYP3A4MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960233-B1 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECH LTD (GB) | 2019-10-30 | — | — | EP | disclosed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-1786773-B1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RES TECH LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| EP-1786773-B1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RES TECH LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-20160355478-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9358222-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-07 | — | — | US | disclosed |
| EP-2960233-A1 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2015-12-30 | — | — | EP | disclosed |
| US-20140194486-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-07-10 | — | — | US | disclosed |
| US-8618158-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-12-31 | — | — | US | disclosed |
| US-20110224274-A1 | New Therapeutic Agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| EP-2315749-A2 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2009156735-A2 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-30 | — | — | WO | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| WO-2006024837-A1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| US-4505921-A | Sulfonylurea compounds and their use in treating diabetes | ADIR, S.A.R.L. (FR) | 1985-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194486-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | CFTR 1621/4885GOPC 2675/4885GAA 2043/4885 |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | HCN3, NHERF1, SIGMAR1 | CFTR 408/4885GOPC 4613/4885GAA 3619/4885 |
| US-20110224274-A1 | New Therapeutic Agents | TP53, MDM2, TP53BP1 | CFTR 1593/4885GOPC 3026/4885GAA 2308/4885 |
| US-20180118684-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | CFTR 1621/4885GOPC 2675/4885GAA 2043/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | CFTR 1621/4885GOPC 2675/4885GAA 2043/4885 |
| US-20160355478-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | CFTR 1621/4885GOPC 2675/4885GAA 2043/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | CFTR 3670/4885GOPC 4164/4885GAA 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.